Wang Qun, Huang Zehao, Chair Sek Ying
School of Nursing, Shenzhen University, Shenzhen, China.
The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
BMC Cardiovasc Disord. 2025 Jun 4;25(1):433. doi: 10.1186/s12872-025-04865-8.
This review aimed to evaluate the effects of exercise-based interventions on cancer therapy-related cardiovascular toxicity (CTR-CVT) in individuals with cancer.
Four databases (MEDLINE, Embase, Web of Science, and CENTRAL) were searched to identify eligible studies. Randomized controlled trials examining the effects of exercise-based interventions on CTR-CVT in cancer patients published in English were included. The risk of bias of included studies was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The meta-analysis was performed using statistical software R. The PRISMA statement was followed.
Thirty studies with 2484 participants were included. Our findings revealed that compared to the control group, exercise-based intervention improved VO (mean difference [MD]: 1.62, 95% confidence interval [CI]: 0.94 to 2.30), resting diastolic blood pressure (MD: -4.43, 95% CI: -8.72 to -0.13), and resting heart rate (MD=-3.74, 95% CI: -6.59, -0.89) among individuals with cancer. Evidence on other study outcomes remains unclear.
The findings of this review demonstrate the potential role of exercises in preventing and treating CTR-CVT. Further research is warranted to strengthen the current evidence and fill the gaps identified in this review.
The review protocol was registered in PROSPERO (ID: CRD42022380550).
本综述旨在评估基于运动的干预措施对癌症患者癌症治疗相关心血管毒性(CTR-CVT)的影响。
检索了四个数据库(MEDLINE、Embase、科学网和CENTRAL)以确定符合条件的研究。纳入以英文发表的、研究基于运动的干预措施对癌症患者CTR-CVT影响的随机对照试验。使用Cochrane随机试验偏倚风险工具第2版评估纳入研究的偏倚风险。使用统计软件R进行荟萃分析。遵循PRISMA声明。
纳入了30项研究,共2484名参与者。我们的研究结果显示,与对照组相比,基于运动的干预改善了癌症患者的最大摄氧量(平均差[MD]:1.62,95%置信区间[CI]:0.94至2.30)、静息舒张压(MD:-4.43,95%CI:-8.72至-0.13)和静息心率(MD=-3.74,95%CI:-6.59,-0.89)。关于其他研究结果的证据仍不明确。
本综述的结果证明了运动在预防和治疗CTR-CVT中的潜在作用。有必要进行进一步研究以加强现有证据并填补本综述中确定的空白。
该综述方案已在PROSPERO注册(注册号:CRD42022380550)。